SYDNEY, Nov. 3, 2025 /PRNewswire/ — Pylon Technologies Co., Ltd. (“Pylontech”, SSE: 688063), a global leader in energy storage systems, is pleased to announce the official opening of its Australian subsidiary in Sydney. This milestone represents a major step forward in the company’s global expansion strategy and reinforces its long-term commitment to the Australian and New Zealand energy storage markets.

The establishment of Pylontech Australia signifies the company’s full operational readiness, providing localized sales, technical services, supply chain coordination, and customer support to better serve its partners and clients across the region.

“Australia has been one of the most dynamic energy storage markets in the world, and we are proud to have been part of its journey since our first system was installed here over a decade ago,” said Geoffrey Song, Vice President of Pylontech. “The launch of Pylontech Australia demonstrates our dedication to supporting local partners through closer collaboration, faster service, and more comprehensive solutions.”

Australia has become one of the world’s most mature and fastest-growing energy storage markets, driven by ambitious national energy transition targets. The government aims to cut emissions by 62–70% below 2005 levels by 2035, supported by programs such as the Cheaper Home Batteries initiative that help households join the clean energy transition. With the new subsidiary now fully operational, Pylontech will further accelerate the delivery of residential, commercial, and utility-scale energy storage solutions — contributing to Australia’s progress toward a clean, reliable, and resilient energy future.

“By establishing a local presence, we aim to be closer to our customers — not only geographically, but also strategically,” added Ned Yu, General Manager of Pylontech Australia. “This milestone enables us to serve the market with even greater agility, innovation, and responsiveness.”

The opening of Pylontech Australia reaffirms the company’s mission to empower global energy transformation through safe, reliable, and sustainable energy storage solutions.

About Pylontech

Founded in 2009, Pylon Technologies Co., Ltd. (Pylontech, SSE: 688063) is a pioneering and leading energy storage system provider, integrating electrochemistry, power electronics, and system integration technologies. With over 2 million systems deployed globally, Pylontech has earned recognition for its innovation and quality worldwide. The company’s product portfolio covers residential, commercial & industrial, and grid-scale applications, supporting global partners in achieving sustainable and secure energy transition.

SHANGHAI, Nov. 3, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product candidate developed on its proprietary THANK-u Plus™ platform for relapsed/refractory multiple myeloma (R/R MM), and for CT1190B, an allogeneic CD19/CD20-targeting CAR-T product candidate for relapsed/refractory non-Hodgkin’s lymphoma (R/R NHL). The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouraging efficacy signals.

Data for CT0596 in Relapsed/Refractory Multiple Myeloma

CT0596 is a BCMA-targeted allogeneic CAR-T cell therapy candidate developed based on CARsgen’s THANK-u Plus™ platform and is currently being evaluated in an investigator-initiated trial (IIT) for malignant plasma cell neoplasms. The study has now entered the dose expansion phase with a determined lymphodepletion regimen. Future work will involve dose escalation of the cells to further determine the Recommended Dose (RD).

As of June 24, 2025, the reported clinical trial (NCT06718270) had enrolled 8 R/R MM patients who received CT0596 infusion from the dose-escalation phase. The median number of prior lines of therapy was 4.5 (range: 3-9). Five patients had prior exposure to triple-class drugs (PI, IMiD, and anti-CD38 monoclonal antibody), and five patients had a history of autologous stem cell transplantation. CAR-T cell doses administered were 1.5e8 (n=1), 3e8 (n=5), and 4.5e8 (n=2).

All 8 infused patients were evaluable for efficacy, with a median follow-up time of 2.56 months (range: 0.9-5.9 months). For lymphodepletion, 6 patients received fludarabine (30 mg/m²) and cyclophosphamide (500 mg/m²), while 2 patients received a reduced lymphodepletion dose. Five patients achieved partial response (PR) or above: 3 achieved complete response / stringent complete response (CR/sCR) (all of whom had received the full dose of lymphodepletion), 1 achieved PR, and 1 achieved very good partial response (VGPR). Six patients achieved minimal residual disease (MRD)-negativity at Week 4. No patients got progression disease. Pat 01 has ongoing sCR and MRD negative for nearly 6 months. CAR-T cell expansion was observed in all 8 patients. No dose-limiting toxicities (DLT), treatment discontinuations, or deaths were observed. Four patients experienced Grade 1 cytokine release syndrome (CRS), all of which resolved within 2-10 days.

Previously, in October 2025, CARsgen announced preliminary clinical data for CT0596 in relapsed/refractory primary plasma cell leukemia (pPCL). Two heavily pretreated pPCL patients with high disease burden and rapid progression both achieved sCR after receiving CT0596 treatment.

Data for CT1190B in Relapsed/Refractory Non-Hodgkin’s Lymphoma

CT1190B is a CD19/CD20-targeted allogeneic CAR-T cell therapy candidate developed based on CARsgen’s THANK-u Plus™ platform and is currently being evaluated in multiple IITs for indications including R/R NHL.

As of October 17, 2025, this reported clinical trials (NCT07053670, NCT06734871) had enrolled 14 patients, including 3 with follicular lymphoma (FL), 3 with mantle cell lymphoma (MCL), and 8 with diffuse large B-cell lymphoma (DLBCL). The dose escalation study has been completed, preliminarily determining the recommended lymphodepletion regimen and cell dose.

At the lymphodepletion dose of Fludarabine 30mg/m²×3 days + Cyclophosphamide 500mg/m²×3 days, all three FL patients achieved CR. One of these FL patients had failed immunochemotherapy, a PI3K inhibitor, chemotherapy + autologous hematopoietic stem cell transplantation, and CD3/CD20 bispecific antibody therapy; another FL patient had failed immunochemotherapy + autologous hematopoietic stem cell transplantation and CD19 CAR-T therapy. The peak copy number of expansion in these three patients reached 10³-10⁴ copies/µg gDNA.

At the lymphodepletion dose of Fludarabine 30mg/m²×3 days + Cyclophosphamide 1000mg/m²×2 days (the recommended lymphodepletion dose), 8 patients were enrolled, including 2 MCL patients (cell dose 6e8) and 6 DLBCL patients (cell dose 3e8: 1 patient; 4.5e8: 1 patient; 6e8: 4 patients). The details are below:

• Six patients were evaluable for efficacy, achieving an ORR of 83.3%, comprising 4 patients who achieved CR (2 MCL, 2 DLBCL) and 1 patient who achieved PR (DLBCL).
• Focusing on the 6e8 cell dose, 6 patients were enrolled. Four of them were evaluable for efficacy, and 3 achieved a response, all of which were CR. The remaining 2 DLBCL patients had not reached the timepoint for efficacy assessment. A total of 6 patients received the full lymphodepletion and recommended cell dose, with a median C_max reaching levels on the order of 10⁵ copies/ug gDNA.

The primary safety signals of CT1190B were CRS, cytopenia, and infections. Other adverse reactions, such as immune effector cell-associated neurologic syndrome (ICANS) and graft versus host disease (GVHD) were not observed.

About CT0596

CT0596 is an allogeneic BCMA-targeted CAR-T therapy developed using CARsgen’s proprietary THANK-u Plus™ platform. It is currently being evaluated in investigator-initiated trials for relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals. Further investigation is planned in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells. The company anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.

About CT1190B

CT1190B is a CD19/CD20-targeted allogeneic CAR-T cell therapy developed based on CARsgen’s THANK-u Plus™ platform. Ongoing clinical trials include IITs for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), and for moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc).

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

NEW YORK, Nov. 3, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on November 3rd

• Equities are higher to start November after the S&P 500 added 2.3% in October. These gains were driven by continued interest in AI and signs of simmered trade between the U.S. and China.
• The AI trade will remain in focus this week with several companies reporting earnings. The bulk of S&P 500 companies have reported so far with many exceeding expectations.
• Qnity Electronics will begin trading on the NYSE today following its spinoff from DuPont. Trading under the ticker symbol Q, the company provides solutions for the semiconductor and electronics industries.

Opening Bell
Qnity Electronics (NYSE: Q) celebrates its launch as an independent company

Closing Bell
DuPont (NYSE: DD) rings the Closing Bell

Click here to download the NYSE TV App

VANCOUVER, BC, Nov. 3, 2025 /PRNewswire/ — WAT Medical Enterprise Ltd. proudly announced the publication of a groundbreaking clinical trial in The Journal of Bone & Joint Surgery (JBJS) which demonstrates the significant benefits of the EmeTerm wristband in reducing postoperative nausea and vomiting (PONV) in patients undergoing total hip or knee arthroplasty (THA/TKA) under spinal anesthesia.

The study aimed to evaluate whether the addition of the EmeTerm wristband to conventional antiemetic therapy could enhance prevention of PONV after orthopedic surgeries. This randomized controlled study involving 348 patients undergoing THA or TKA under spinal anesthesia were assigned to receive either (1) standard antiemetics alone (dexamethasone and ondansetron) or (2) antiemetics combined with the EmeTerm bracelet. PONV incidence, severity, and recovery quality were assessed over 24 hours post-surgery.

The combined use of the EmeTerm wristband and antiemetics significantly reduced PONV occurrence and improved overall recovery quality. Specifically: The combination of the EmeTerm wristband and antiemetic medication achieved a significantly higher complete response rate than medication alone (84.0% vs. 68.8%; p = 0.001)(Figure 1). Within the critical first 6 postoperative hours, combined use of the EmeTerm wristband substantially enhanced antiemetic efficacy: Nausea incidence reduced from 24.3% to 6.9%; Vomiting incidence reduced from 15.0% to 2.3%(Figure 2). Level of Evidence is Therapeutic Level l.

The study concludes that EmeTerm can significantly enhance the effectiveness of standard antiemetic protocols for orthopedic patients under spinal anesthesia. This study provides rigorous evidence that the EmeTerm wristband can meaningfully enhance standard antiemetic therapy and improve recovery outcomes after orthopedic procedures. The findings open a new pathway for integrating non-pharmacological interventions into perioperative care.

The EmeTerm wristband, developed by WAT Medical Enterprise, delivers transcutaneous electrical acupoint stimulation (TEAS) at the median nerve PC6 position on the wrist to regulate nausea pathways through neural modulation. The device has received medical device certifications from the FDA, HC, TGA and actively renewing its CE certification, which expected to be completed in Q1 2026.

This study provides strong evidence that the EmeTerm wristband effectively enhances the performance of standard antiemetic regimens, offering a drug-free, reusable, and patient-friendly solution for managing PONV. By integrating EmeTerm into perioperative care, hospitals can help patients recover faster and more comfortably, while reducing dependence on medication. This approach aligns with global trends toward multimodal, patient-centered recovery.

Leader in Smart Home Cleaning Rolls Out the Red Carpet for Celebrity Pets, “Cover Pup” Auditions, Free Grooming, and Exclusive Prizes 

NEWPORT BEACH, Calif., Nov. 3, 2025 /PRNewswire/ — Roborock, the global leader in smart home cleaning technology, is excited to welcome Southern California residents to its first-ever interactive, pet-focused “Pawp-Up” event at Fashion Island in Newport Beach, California. This free, three-day experience, taking place from November 7–9, 2025, invites pet owners to celebrate their furry friends and discover the brand’s powerful cleaning solutions designed to tackle pet hair, pawprints and everyday messes.

Known for its #1 selling robot vacuums worldwide, Roborock is teaming up with Maui the Golden (@maui_thegoldenpup) on Nov. 7 and I’m Blue the Siberian (@imbluethesiberian) on Nov. 8 to offer pet parents a fun and immersive way to interact with its newest products while enjoying unique pet-centric activities. At the heart of the event is the exclusive Cover Pup Studio, where one distinguished pooch will be crowned the first official “Cover Pup” in Roborock’s new Home & Hound Magazine. Competing for this coveted title, all attendees will receive a personalized, magazine-style cover shoot with their furry friend.

Visitors can also explore interactive zones for pets and their owners to engage directly with Roborock’s innovative cleaning solutions including the Saros Z70, Saros 10R, Qrevo CurvX, F25 Ultra, F25 RT, Q10 PF+, and the QR 798.

“We’re thrilled to bring the Roborock experience beyond the home for the first time as we head to Newport Beach to connect with our beloved community of pet owners,” said Quan Gang, President of Roborock. “Our smart cleaning technology is designed to make life easier for busy, pet-loving families. Through fun, engaging experiences, we invite Southern California residents to celebrate the joy of life with our furry friends and discover how Roborock helps keep their homes effortlessly clean.”

Attendees can also look forward to:

• Complimentary Grooming: Get your pooch looking posh with local grooming provided by Newport Paws.
• Pet Performances: Show off all your pet’s tricks at this live talent showcase.
• Exclusive Giveaways: Enter to win top-tier Roborock products, such as the Saros Z70 which is valued at $2,500.

Event Details

• Location: Fashion Island, 401 Newport Center Dr., Newport Beach, CA 92660
• Dates and Times:
  • Friday, Nov. 7: 11 a.m. – 5 p.m.
  • Saturday, Nov. 8: 10 a.m. – 5 p.m.
  • Sunday, Nov. 9: 10 a.m. – 5 p.m.
• Admission: Free and open to the public. Pets are welcome!

As homes continue to evolve into smarter, more compassionate spaces, Roborock aims to be more than a cleaning brand — it strives to be a trusted partner for every modern pet family. By combining intelligent technology with thoughtful design, Roborock empowers pet owners to spend less time worrying about the mess and more time cherishing the moments that matter. The “Pawp-Up” experience reflects this belief, transforming everyday cleaning into a shared celebration of love, comfort, and connection between people, pets, and their homes.

For more information on Roborock and to explore the brand’s full product portfolio, visit https://us.roborock.com/.

About Roborock

Roborock is a leading smart cleaning brand renowned for its intelligent cleaning solutions. With a steadfast dedication to becoming a global leading smart appliance player, Roborock enriches lives with its innovative line of robotic, cordless, wet/dry vacuum cleaners, and washer-dryers. Rooted in a user-centric approach, our R&D-driven solutions cater to diverse cleaning needs in over 15 million homes across 170+ countries. Headquartered in Beijing and with strategic subsidiaries in key markets, including the United States, Japan, the Netherlands, Poland, Germany, and South Korea, Roborock is dedicated to elevating its market presence worldwide. For more information, visit https://global.roborock.com/. 

Media Contact:

Ashley Hu
646-702-8832
hujingjie@roborock.com

Key Points

• Backed by the intelligence of the IBM Cloudability platform and integration with Terraform, Cloudability Governance helps FinOps teams and engineers proactively understand cloud cost implications, forecast and comply with internal policies before deploying infrastructure.
• IBM Kubecost 3.0 represents the most comprehensive evolution of Kubecost to-date, delivering capabilities and enhancements to set a new Apptio standard for applying FinOps practices to Kubernetes deployments.
• New Apptio FinOps solutions are purpose-built for AI demand, empowering organizations with end-to-end visibility across cloud environments to derive practitioner efficiencies and actionable insights.

BELLEVUE, Wash., Nov. 3, 2025 /PRNewswire/ — Apptio, an IBM company (NYSE: IBM), today unveiled next-generation FinOps solutions from IBM Cloudability and IBM Kubecost designed to enhance visibility and optimize cloud costs across complex, AI-driven environments. 

Apptio, an IBM company

As enterprises accelerate AI development, IT leaders are under increasing pressure to manage escalating costs effectively. IDC estimates that enterprise investments in AI infrastructure will reach $571 billion globally in 2026. Yet, according to an Apptio study, 55% of business leaders surveyed say they lack the information needed to evaluate technology spend effectively. FinOps provides an operational framework to address these challenges by empowering organizations with real-time visibility, financial accountability and management of cloud costs, maximizing business value and collaboration.

“Generative AI is not only pushing the limits of cloud infrastructure; it’s challenging the ability of technology and business leaders to make informed decisions and evaluate tech spend ROI. The AI era is one of information and compute-power overload,” said Eugene Khvostov, Chief Product Officer at Apptio. “So, it’s imperative for organizations to gain control over their cloud and data estate. That’s the first step in harnessing the AI opportunity and exactly what our new FinOps solutions are designed to address – proactive, and predictive cloud cost management.” 

Cloudability Governance: Proactive Control Across Multi-Cloud Environments

Infrastructure as Code helps teams scale cloud infrastructure with speed and consistency. But without FinOps alignment, there can be financial blind spots—where teams deploy at speed but may lack insights into the financial impact of their infrastructure decisions.

Backed by Cloudability and now integrated with HashiCorp Cloud Platform (HCP) and Hashicorp Terraform, Cloudability Governance is specifically designed to empower FinOps teams with greater control over cloud infrastructure deployments by automating cost compliance monitoring and applying defined organizational policy – all within the engineering workflow. This includes: 

• Reliably scale infrastructure using infrastructure as code. Centralized state management, secure execution, and team collaboration support consistent, deployments—and can help reduce risk and accelerate delivery across complex cloud environments.
• Enact informed policies for infrastructure provisioning with built-in checks that guide or enforce best practices like ensuring the correct organizational tags are applied. Integrate personalized cost estimates and financial guardrails to help teams make informed, proactive decisions and stay aligned with budgets before deployment.
• Control cloud spend with near real-time visibility into actual cloud costs after deployment and AI-powered recommendations to uncover opportunities to address waste, even ahead of deploying infrastructure. Detect anomalies, track spend against expectations and validate infrastructure decisions based on detailed billing data—helping teams stay accountable and optimize their cloud investments.

“Our customers want accurate, real-time visibility into the cost implications of the infrastructure they manage and deploy with HashiCorp Terraform,” said Armon Dadgar, CTO and co-founder of HashiCorp, an IBM company. “With native bi-directional integration between HashiCorp Terraform and Cloudability, engineers gain visibility into infrastructure costs, embedded governance checks, and optimization opportunities directly within their workflows.”

Kubecost 3.0: Setting a New Standard for Kubernetes Cost Management  

Kubecost 3.0 represents the most advanced evolution of Kubernetes cost management to date, built to help enterprises tackle the complexities of managing their Kubernetes environments at scale. With this latest version, Kubernetes teams gain access to: 

• Enhanced tools for unified resource management that provide a comprehensive view across clusters, streamlining cost allocation and resource utilization.
• Advanced savings recommendations, enabling precise identification of opportunities to optimize usage and eliminate inefficiencies.
• Comprehensive savings recommendations, featuring automated container right-sizing, advanced GPU monitoring and optimization powered by NVIDIA’s DCGM exporter, and enhanced node group sizing insights. These new capabilities were built for teams to quickly identify inefficiencies and take action to address costs across all workloads.
• Enhanced capabilities for scalability and security, helping to ensure that organizations can grow their Kubernetes deployments while prioritizing security and operational control in even the most complex cloud environments.

Cloudability Governance integration with HCP and Terraform Enterprise is available today in public preview. Kubecost 3.0 is generally available now. Apptio will demonstrate the new solutions at the annual TBM Conference and at KubeCon North America (Booth 800), showcasing how organizations can leverage FinOps for strategic business advantage. 

To learn more about Cloudability Governance, Kubecost 3.0, and how Apptio is transforming FinOps for the AI era, visit the Apptio Innovation Hub.

About Apptio, an IBM Company
Apptio, an IBM company, is a leading technology spend and value management software provider. Apptio’s AI-powered data insights empower leaders to make smarter financial and operational decisions across Information Technology (IT), multi-cloud FinOps, and digital product development. Apptio’s mission is to deliver business value with every technology investment and team. Powered by Apptio’s cloud platform, Apptio’s SaaS applications help translate technology spend into clear business outcomes and financial ROI. As a pioneer and category leader in Technology Business Management (TBM), FinOps, and Agile Portfolio Management, Apptio works with thousands of customers, partners, and community members worldwide.  

CONTACT: Jas McDonald, Jas.McDonald@ibm.com 

1. According to IDC’s Worldwide AI and Generative AI Spending Guide, published in August 2025